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Abstract: N-cyanomethylmethamphetamine (CMA) is a main pyrolysis product of smoking methamphetamine (MA) 
mixed with tobacco, and it has MA-like central stimulant effects, acceleration of ambulation and production of various 
types of stereotyped behavior, and induction of sensitization to these behavioral effects following repeated administration 
in mice and rats.  The induction of behavioral sensitization to central stimulants has been considered to be intimately 
related to the development of the psychotoxic symptoms following repeated abuse of these drugs.  Since CMA is inhaled 
simultaneously with nicotine, the aim of this study was to investigate the modifications by nicotine of induction and 
expression of sensitization to the ambulation-increasing effect of CMA in mice.  During the 5 repeated co-administrations 
of CMA (3 mg/kg s.c.) with nicotine (0.03, 0.1, 0.3 and 1 mg/kg s.c.) at 3 day intervals, nicotine dose-dependently 
inhibited the progressive enhancement of CMA-induced ambulatory stimulation. However, such treatments did not 
modify the induction of sensitization to the ambulatory stimulant effect of MA (2 mg/kg s.c.).  The MA-sensitized mice 
demonstrated significant cross-sensitization to CMA.  In both the drug-naive and MA-sensitized mice, nicotine reduced the 
ambulatory stimulant effect of CMA.  These results suggest that, although nicotine acts to reduce the ambulatory stimulant 
effect of CMA, nicotine does not protect the induction of behavioral sensitization to CMA and MA.  The repeated 5 
times experience of nicotine (1mg/kg s.c.) alone did not modify the sensitivity of mice to CMA or MA.  These results 
also indicate that nicotine does not modify the psychotoxic liability of MA following repeated smoking MA mixed with 
tobacco, although nicotine may reduce the reward effect of MA.
(Reprint request should be sent to Hisashi Kuribara)
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Introduction
Methamphetamine (MA) abuse is the most serious drug 
abuse problem in Japan.  The repeated abuse of MA has a 
high risk of induction of psychotoxic symptoms such as 
paranoid, hallucination, etc. (Robinson and Becker, 1986; 
Tadokoro and Kuribara, 1986).  Mesolimbic dopaminergic 
systems (Van der Heuval and Pasterkamp, 2008) play sig-
nificant roles not only in the reward effect of drugs, i.e., 
substance abuse liability (Ikemoto, 2007; Piercem and 
Kumaresan 2006; Berridge, 2007), but also in the behav-
ioral and psychological activities, particularly, motivation 
(Matsumoto and Hikosaka, 2009), attention and learning 
and memory (Arias-Carrion and Poppel, 2007; Ikemoto, 
2007).  It is therefore important to assess the changes in 
the behavioral effect following the repeated administration 
of central stimulants including MA and related drugs.
Although MA has traditionally been administered intra-
venously, an inhalation of MA vapor, namely ABURI, or 
mixed with tobacco, namely MOKU, is increasing not only 
because to avoid infections and the trace of picking needle, 
but because of easier way for taking the drug (personal 
communication from Japanese Ministry of Police).
N-cyanomethylmethamphetamine (CMA) (Fig. 1) is a 
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main pyrolysis product of smoking MA mixed with tobacco 
(Sekine and Nakahara, 1987, 1990; Sekine et al., 1995). 
The behavioral examinations in mice and rats revealed that 
CMA had MA-like central stimulant effect at comparatively 
lower doses; acceleration of ambulatory activity (locomo-
tion) with the peak effect at 1.5 hr after the subcutaneous 
(s.c.) administration, and induction of various types of 
stereotyped behavior at higher doses (Nakahara and Sekine, 
1987).  The potency of behavioral stimulant effect of CMA 
was estimated to be approximately 2/3 time as high as that 
of MA (Nakahara and Sekine, 1987; Kuribara et al., 
1996a).  Our previous experiments demonstrated that inter-
mittent administrations of CMA at intervals of 3-4 days 
induced the behavioral sensitization to the ambulatory 
stimulant effect in mice (Kuribara et al., 1996a, b). 
The central stimulant effect of amphetamines is caused 
by an acceleration of dopamine release from the presynap-
tic cytoplasmic pool at mesolimbic dopaminergic system 
(McMillen, 1873).  Nicotine, an agonist of nicotinic ace-
tylcholine receptors (Fuxe et al., 1986; Imperato et al., 
1986; Marks et al., 1986), also accelerates dopamine re-
lease in the brain through stimulation of nicotinic acetyl-
choline receptors (Marks et al., 1986; Mereu et al., 1987; 
Rowell et al., 1987; Carr et al., 1989; Kita et al., 1990; 
Sershen et al., 1991; Jutkiewicz et al., 2008), and shows an 
ambulatory stimulant effect in rodents, particularly in rats 
(Clarke et al., 1988; Kita et al., 1990, 1992; Ann-Sophie et 
al., 2006).  Such neurochemical and behavioral character-
istics of nicotine are partially similar to those of amphet-
amines.  However, some reports suggested an antagonistic 
effect of nicotine on the amphetamine-induced ambulatory 
stimulation (Stolerman et al., 1973; Stevens et al., 1995), 
stereotyped behaviors (Arnfred and Rundrup, 1968; Kla-
wans et al., 1972), and impairment of auditory sensory gat-
ing (Stevens et al., 1995).
Since CMA is a main pyrolysis product of smoking MA 
mixed with tobacco and is inhaled simultaneously with 
nicotine, it is extremely important to evaluate the com-
bined effect of CMA and nicotine in relation to the 
modification of the behavioral stimulant effects of CMA 
and MA.
The aims of this study were to assess the characteristics 
of modification by nicotine of the induction and expression 
of ambulatory sensitization to CMA and MA in mice.  The 
following two experiments were conducted: 1) repeated 
co-administrations of CMA with nicotine, and then chal-
lenge administration of MA, and 2) co-administration of 
CMA with nicotine to the MA-sensitized mice.
Materials and Methods
Animals
Male mice of ddY strain (Japan Laboratory Animals, 
Tokyo) were used at the age of 6 weeks (weighing 25-30 g). 
These mice were housed in groups of 10 in Polycarbonate 
cages (20W × 25L × 10H cm).  The conditions of breed-
ing room of Institute of Experimental Animal Research, 
Gunma University School of Medicine were controlled to 
temperature of 23 ± 2℃ , relative humidity of 55 ± 3%, 
and 14:10 hr light-dark cycle of lights on between 
05:00-19:00 hr.  They were allowed free access to a solid 
diet (MF: Oriental Yeast, Tokyo) and tap water except dur-
ing the behavioral tests.
Apparatus
The ambulatory activity of 10 mice was individually and 
simultaneously recorded with a tilting-type ambulometer 
having 10 bucket-like activity cages of 20 cm in diameter 
and 15 cm in height (SMA-10: O’hara & Co., Tokyo).  A 
horizontal movement (ambulation) for longer than 5 cm, 
but not any vertical movements or turning, of the mouse 
generated a slight tilt of the activity cage, and it was de-
tected with one of 3 micro-switches attached to the activity 
cage.
Fig. 1.  Chemical structures of N-cyanomethylmethamphet-
amine (CMA), a main pyrolysis product of smoking 





The drugs used were N-cyanomethylmethamphetamine 
hydrochloride (CMA: synthesized by Criminal Investiga-
tion Laboratories of Saitama Prefectural Police HQ, Saita-
ma), methamphetamine hydrochloride (MA: Philopon; 
Dainippon-Sumitomo Pharm., Osaka) and nicotine free 
base (Nakarai Chemical., Tokyo).  CMA, MA and nicotine 
were dissolved in physiological saline, and the concentra-
tion of each drug solution was adjusted so that the volume 
subcutaneously (s.c.) injected was always constant at 0.1 
ml/10 g body weight of the mouse.  According to the pre-
vious studies related to CMA (Kuribara et al., 1996a, b) 
and MA (Kuribara and Hirabayashi, 1985), the doses of 
CMA and MA were fixed to 3 mg/kg and 2 mg/kg, respec-
tively, in the salt forms, which were considered to be al-
most equivalent doses for increasing the ambulatory 
activity, and optimal doses for induction of ambulatory 
sensitization without eliciting strong stereotyped behaviors 
throughout the 5 repeated administrations at 3-day inter-
vals in the ddY strain mice.
Experimental schedules 
Before each drug administration, mice were adapted to 
the activity cage for 10 min.  Then the ambulation of each 
mouse was measured for 3 hr after each drug administra-
tion.  All the behavioral tests were carried out between 
09:00-16:00 hr. 
Experiment 1.  Repeated co-administrations of CMA with 
nicotine, and followed by the challenge ad-
ministration of MA
Five groups of mice (10 each) were first treated with 5 
repeated administrations of either CMA alone (nicotine 
dose=0) or CMA in combination with nicotine (0.03, 0.1, 
0.3 or 1 mg/kg) at 3-day intervals.  Three days after the 5th 
treatment, all the mice were challenged with MA alone.  In 
addition, the administration of MA to the drug-naive mice 
(N=10) that were age-matched to the mice treated with the 
co-administrations of CMA with nicotine was also con-
ducted. 
Experiment 2.   Combined administration of CMA with 
nicotine to the MA-sensitized mice
To induce the ambulatory sensitization to MA, 5 groups 
of mice (10 each) were first treated with 5 repeated admin-
istrations of MA at 3-day intervals in the same way as in 
experiment 1.  Three days after the 5th treatment, these 
groups of mice were challenged with either CMA (nicotine 
dose=0), or combination of CMA with nicotine (0.03, 0.1, 
0.3 or 1 mg/kg). 
Experiment 3.   Combined administration of nicotine and 
CMA or MA to the mice experienced 5 
treatments with nicotine
Five groups of 10 mice each were given nicotine (1 mg/
kg s.c.) or saline 5 times at intervals of 3 days, and their 
ambulatory activities were measured for 3 hr after each ad-
ministration.  Three days after the 5th treatment, the 
groups of mice were given either saline, CMA (3mg/kg 
s.c.), MA (2 mg/kg s.c.), nicotine + CMA or nicotine + 
MA.
Ethical consideration for experimental animals
All the experimental procedures mentioned above were 
carried out according to the “Guiding Principles for the 
Care and Use of Laboratory Animals” approved by The 
Japanese Pharmacological Society.
Statistical analysis
Mean 3-hr overall ambulatory activity counts after the 
drug administrations were first analyzed by one- or two-
way analysis of variance.  In cases of significant variance, 
post-hoc analyses were carried out by Bonferoni test. Val-
ues of p less than 0.05 were considered significant. 
Results
1)  Repeated co-administrations of CMA with nicotine, 
and then challenge with MA (Experiment 1)
As shown in Table 1, the repeated co-administrations of 
CMA with nicotine caused a progressive enhancement of 
the ambulatory stimulant effect, although nicotine reduced 
the effect of CMA in a dose-dependent manner.  When the 
challenge administration of MA was conducted, there was 
no significant difference in the activity counts among 
groups of mice treated with CMA alone or combination of 
CMA with nicotine, and the activity counts were almost 
the same as that in the mice received 5 repeated adminis-
tration of MA at 3 day-intervals.
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2)  Combined administration of CMA with nicotine to 
the MA-sensitized mice (Experiment 2)
Five repeated administrations of MA (2mg/kg s.c.) at 
3-day intervals resulted in an ambulatory sensitization to 
MA in all groups of mice; the activity counts at the 1st and 
5th administration being 1600-1800 and 4000-4200, re-
spectively (data are not shown). 
Table 2 shows mean 3-hr activity counts after the ad-
ministration of CMA alone (nicotine dose=0) or CMA in 
combination with nicotine (0.03-1 mg/kg) to the MA-sen-
sitized mice.  For comparison, the activity counts after the 
combined administration of CMA with nicotine to the 
drug-naive mice, which are shown in Table 1 (the counts at 
the 1st administration), are also presented.
The MA-sensitized mice demonstrated a significant 
cross-sensitization to CMA. The ambulatory stimulant ef-
fect of CMA was reduced by nicotine in both the drug-na-
ive and MA-sensitized mice. The activity counts following 
Table 1.  Mean 3-hr ambulatory activity counts±SEMs after 5 repeated administrations of N-cyanomethylmetham-
phetamine (CMA: 3 mg/kg s.c.) alone and the combinations of CMA with nicotine (NCT: 0.03, 0.1, 0.3 and 
1 mg/kg s.c.), and MA (2mg/kg s.c.) at 3-day intervals, and challenge administration of MA.
Drugs and doses 1st 2nd 3rd 4th 5th MA-challenge
CMA only 1318±188 1832±265 3462±499* 3829±554* 3941±601* 4505±551#
CMA+NCT (0.03) 1301±120 1752±243 2992±449* 3948±562* 3880±554* 4462±604#
CMA+NCT (0.1) 1057±169 1493±214 2258±309*,$ 3503±505* 3516±527* 4517±553#
CMA+NCT (0.3)  917±108$ 1206±161$ 2301±355*,$ 3046±436* 3004±446* 4491±598#
CMA+NCT (1)  836±125$  995±139$ 1592±259*,$ 2517±359*,$ 2494±384*,$ 4520±528#
MA only 1806±113 2607±372* 4208±429* 4495±518* 4713±496* 4520±528#
MA to the drug-naive mice 1849±207
CMA and NCT were administered simultaneously. 
*:  Significantly different from the count in the first administration within each group (p<0.05).
$:  Significantly different from the count of CMA alone-treated group at the same administration number (p<0.05).
#:  Significantly different from the count after the administration of MA to the drug-naive mice (p<0.05). 
N=10 in each group.
Table 2.  Mean 3-hr ambulatory activity counts ± SEMs after the administration 
of N-cyanomethylmethamphetamine (CMA: 3 mg/kg s.c.) alone, co-
administration of CMA with nicotine (NCT: 0.03-1 mg/kg s.c.), or 
nicotine alone to the methamphetamine (MA)-sensitized mice.
Drug naive MA-sensitized
CMA alone 1318±265 4096±614
CMA + NCT (0.03) 1452±243 3617±523
CMA + NCT (0.1) 1493±214 3108±436
CMA + NCT (0.3)  917±108* 2620±403*
CMA + NCT (1)  836±125* 2283±312*
The sensitization to MA was induced by 5 repeated administrations of MA 
(2 mg/kg s.c.) at 3-day intervals, and the co-administrations of CMA with NCT, 
and NCT alone were carried out 3 days after the 5th pretreatment with MA. 
*:  Significantly different vs. the group administered CMA alone (p<0.05). 
N=10 in each group.
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the co-administration of CMA with nicotine 0.3-1 mg/kg 
in the drug-naive and CMA-sensitized mice were signifi-
cantly lower than those following the administration of 
CMA alone.
3)  Combined administration of nicotine and CMA or 
MA to the mice experienced 5 treatments with nico-
tine (Experiment 3)
The activity counts following nicotine or saline were 
very low; 110-130 counts/3 hr after nicotine, and 90-105 
after saline (Data are not shown).
As shown in Table 3, the mice experienced 5 times treat-
ment with nicotine (1mg/kg s.c.) did not change the sensi-
tivity to CMA or MA.  Furthermore, the combined 
administration of nicotine and CMA or MA did not dem-
onstrate a marked change in the activity as compared to the 
saline-treated mice.
Discussion
In agreement with our previous studies (Kuribara et al., 
1996a,b), the repeated administrations of CMA induced an 
ambulatory sensitization similar to the repeated adminis-
trations of MA (Kuribara and Hirabayashi, 1985).  The 
central stimulant effect of MAP is caused by acceleration 
of dopamine release from the cytoplasmic pool (McMillen, 
1983).  It is generally considered that the nicotine-induced 
behavioral stimulation is caused by an acceleration of do-
paminergic neurotransmission through stimulation of ace-
tylcholine release in the brain (Fuxe et al., 1986; Imperato 
et al., 1986; Carr et al., 1989; Mereu et al., 1987; Rowell et 
al., 1987; Kita et al., 1990, 1992; Sershen et al., 1991).  In 
rats, generally, amphetamine and nicotine interact to en-
hance their behavioral and neurochemical effects (Huston-
Lyons et al., 1993; Anne-Sophie et al., 2006).  In these 
respects, we first expected that nicotine might not only en-
hance the ambulatory stimulant effect of CMA but also ac-
celerate the induction of behavioral sensitization to CMA.
However, it is notable that the ambulatory stimulant ef-
fect of CMA was significantly reduced by nicotine in the 
drug-naive mice (see the 1st administration shown in Table 
1), the MA-sensitized mice (Table 2), and the nicotine-
treated mice (Table 3), suggesting that nicotine acts to in-
hibit the ambulatory stimulant effect of CMA in mice. 
These results are in consistent with the inhibitory effects of 
nicotine on the amphetamine-induced locomotor stimula-
tion (Stolerman et al., 1973), stereotyped behavior (Arnfred 
and Rundrup, 1968; Klawans et al., 1972), and impairment 
of auditory gating in rats (Stevens et al., 1995).
Some mechanisms can be considered to be involved in 
the antagonistic effect of nicotine on the behavioral stimu-
lation caused by amphetamines including CMA. The first 
one is that the nicotine-induced dopamine release through a 
stimulation of the nicotinic acetylcholine receptors in the 
brain is responsible for the reduction of amphetamine-in-
duced dopamine release (Sershen et al., 1991).  The second 
one is a possibility that the anti-stress effect of nicotine 
(Benovitz et al., 1986) plays to inhibit the behavioral stimu-
lant effect of amphetamines.  It has been suggested that hy-
pothalamic-pituitary adrenal axis is involved in the 
induction and expression of sensitization to amphetamines 
(Knich and Eisenberg, 1979; Rivet et al.. 1989; Cole et al., 
1990a, b; Kalivas and Eisenberg, 1991).  Anne-Sophie et al. 
(2006) suggested a role of serotonergic mechanism in the 
Table 3.  Mean 3-hr ambulatory activity counts ± SEMs after the administration of N-cyanomethylmethamp
hetamine (CMA: 3 mg/kg s.c.), methamphetamine (2mg/kg s.c.), or co-administration of CMA or 
MA with nicotine (NCT: 1 mg/kg s.c.) to the mice pre-treated with NCT (1mg/kg s.c.).
Pretreatments
Challenge administrations
Saline  CMA MA NCT+CMA NCT+MA
Saline 73±15 1309±163 1830±142 872±141* 1008±127*
NCT 56±11 1252±140 1903±179 901±155* 1137±152*
The pretreatment were carried out 5 times at 3-day intervals, and the challenge administrations were 
carried out 3 days after the 5th pretreatment.
*:  Significantly different between groups of CMA/NCT+CMA and MA/NCT+MA (p<0.05). 
N=10 in each group.
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nicotine-induced locomotor-increasing effect in mice.  Fur-
ther study is required to elucidate the antagonistic effect of 
nicotine on the amphetamine-induced behavioral stimula-
tion in mice.
The central stimulant effect of amphetamines is caused 
by an acceleration of dopamine release from the presynap-
tic cytoplasmic pool at mesolimbic brain system (McMil-
len, 1873).  Mesolimbic dopaminergic systems in the brain 
(Van der Heuval and Pasterkamp, 2008) play significant 
roles in the substance abuse liability (Ikemoto, 2007; Pier-
cem and Kumaresan 2006; Berridge, 2007).  The behavior-
al sensitization to amphetamines and related compounds 
has been considered to be related not only to the risk of the 
psychotoxic symptoms, namely amphetamine psychosis, 
induced by the repeated abuse of amphetamines (Ellinwood 
and Kilbey, 1977; Kuribara and Hirabayashi, 1985; Robin-
son and Becker, 1986; Tadokoro and Kuribara, 1986), but 
also to the enhancement of the abuse liability (Wise and 
Bozarth, 1987).
The present study revealed that, although nicotine inhib-
ited the acute ambulatory stimulant effect of CMA and 
MA, and the repeated treatment with nicotine did not 
change the sensitivity to the stimulant effect of CMA or 
MA, the ambulatory sensitization to MA was not modified 
by the repeated co-administration of CMA and nicotine. 
These results also suggest that nicotine does not change 
the process of the induction of the behavioral sensitization 
to MA.  Taken together, it is highly probable that the re-
peated smoking MA mixed with tobacco (i.e., the com-
bined abuse of CMA with nicotine) may not reduce the 
liability of MA abuse and MA-induced psychotoxic symp-
toms such as paranoid, hallucination, etc. 
This result also indicates another problem of MA abuse 
mixed with tobacco. Thus, to maintain the reward effect of 
these drugs, the combined MA abuse mixed with tobacco 
may increase the MA dose, and accelerate the risk of the 
MA-induced psychotoxic symptoms.
Conclusion
Behavioral sensitization to central stimulants such as 
amphetamines has been considered to be intimately related 
to the induction of psychotoxic symptoms following re-
peated abuse.  MA-like behavioral sensitization was also 
induced to CMA, a main pyrolysis product of smoking MA 
mixed with tobacco, when it was administration at interval 
of 3 days in mice.  During the 5 repeated co-administration 
of CMA (3 mg/kg s.c.) with nicotine (0.03, 0.1, 0.3 and 1 
mg/kg s.c.) at 3 day intervals, nicotine dose-dependently 
inhibited the progressive enhancement of CMA-induced 
ambulatory stimulation.  However, such treatments did not 
modify the induction of sensitization to the ambulatory 
stimulant effect of CMA (3 mg/kg s.c.) and MA (2 mg/kg 
s.c.).  The MA-sensitized mice demonstrated significant 
cross-sensitization to CMA.  These results suggest that, al-
though nicotine inhibited the ambulatory stimulant effect of 
CMA in both the drug-naive and MA-sensitized mice, nico-
tine does not protect the induction of behavioral sensitiza-
tion to CMA or MA.  These results also indicate that 
repeated smoking MA mixed with tobacco may not modify 
the process of the induction of psychotoxicity of MA.
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